On September 13, 2021, aTyr Pharma announced positive results from their Phase1b/2a clinical trial for ATYR1923 in pulmonary sarcoidosis. FSR is proud to have supported this clinical trial. The trial demonstrated that ATYR1923 was safe and well-tolerated, 33%...
My journey with Interstitial Lung Disease (ILD) started about 15 years ago, although I did not know it at the time, nor did the physicians who were then treating me. At an annual physical, at the age of 46, I mentioned that my knees were a bit sore after physical...
Updated January, 2022 What to know about Omicron, the vaccines, the boosters, and staying safe The Omicron variant of the COVID-19 virus is now the dominant variant in the United States and since December cases have been skyrocketing. Vaccines and boosters ...
Sarcoidosis does not automatically indicate an immunocompromised diagnosis. FSR cannot determine or provide recommendations for your individual immunocompromised status. Please consult your physician for personalized medical advice. On Friday, August 13, 2021, the...
